Related Experiment Videos

The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary

Matthew T Roe1, Eric D Peterson, L Kristin Newby

  • 1Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. roe00001@mc.duke.edu

American Heart Journal
|June 20, 2006
PubMed

Insights

High-risk patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) often do not receive guideline-recommended treatments. This study highlights disparities in care for these vulnerable patients, indicating a need for improved quality improvement strategies.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Health Services Research

Background:

  • Practice guidelines recommend evidence-based therapies for high-risk patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS).
  • Guideline adherence for NSTE ACS treatment based on patient risk status has not been fully characterized.

Purpose of the Study:

  • To assess adherence to NSTE ACS guidelines based on patient risk stratification.
  • To identify potential disparities in care for high-risk NSTE ACS patients.

Main Methods:

  • Analysis of inhospital treatments and outcomes for 77,760 NSTE ACS patients from the CRUSADE initiative (2001-2003).
  • Evaluation of compliance with ACC/AHA guideline recommendations.
  • Risk stratification using an adapted PURSUIT risk model to predict inhospital mortality.

Main Results:

  • High-risk features (diabetes, renal insufficiency, heart failure, age ≥75) were associated with increased inhospital mortality.
  • Use of guideline-recommended acute and discharge therapies, and invasive procedures was lower in high-risk patients.
  • Patients identified as high-risk for mortality were less likely to receive guideline-recommended therapies compared to lower-risk patients.

Conclusions:

  • Patients with NSTE ACS at the highest risk of mortality are less likely to receive guideline-recommended therapies and interventions.
  • There is a need to refine guideline recommendations for high-risk NSTE ACS patients.
  • Novel quality improvement strategies are required to address undertreatment in specific patient subgroups.
Abstract

Related Concept Videos

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...